Education
About Us
Working with TipRanks
Follow Us
Staar Surgical (STAA)
NASDAQ:STAA
Earnings Data
Report Date
May 06, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.07Last Year’s EPS
-0.52Same Quarter Last Year
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed cautious optimism and a constructive tone: the company delivered solid quarter-over-quarter and year-over-year operational improvements (notably strong Q4 sales growth, significant China quarter recovery, gross margin expansion, near-breakeven adjusted EBITDA, cash strength and cost discipline) while acknowledging material challenges that impacted 2025 (China channel inventory rebalancing, distributor returns, EMEA disruption and merger-related costs). Management outlined clear actions—Swiss manufacturing, product launches (EVO+), ERP and platform investments, and maintained cost discipline—aimed at driving growth and profitability in 2026, though near-term headwinds and macro uncertainty, particularly in China and some channel risks, remain.Company Guidance
Quarterly Revenue Growth
Total net sales of $57.8 million in Q4 FY2025 versus $49.0 million a year ago, an increase of ~17.96% year-over-year, driven largely by China recovery and stronger Americas performance.
Strong China Recovery (Quarter)
China net sales of $17.5 million in Q4 versus $7.8 million a year ago, a ~124% year-over-year increase, reflecting in-market demand recovery despite channel inventory dynamics.
Profitability and Adjusted EBITDA Improvement
Adjusted EBITDA improved materially to a loss of $0.2 million in Q4 from a loss of $20.8 million in the year-ago quarter, driven by higher gross profit and lower operating expenses (ex-merger/restructuring). Management is targeting full-year profitability in FY2026.
Gross Margin Expansion
Gross profit margin increased to 75.7% of net sales in Q4 versus 64.7% in the prior-year quarter, an improvement of ~11.0 percentage points, aided by timing of cost recognition, cost reductions and Swiss manufacturing ramp.
Operating Expense Discipline
Excluding merger and restructuring costs, Q4 operating expenses were $54.7 million, an 8.2% reduction versus prior-year quarter. The company reduced its annualized adjusted operating expense run rate and beat its second-half $225 million run-rate target.
Strong Balance Sheet
Cash, cash equivalents and marketable securities of approximately $187.5 million at quarter end; STAAR has no debt and maintained cash levels despite restructuring and merger-related expenses.
Manufacturing and Supply-Chain Improvements
Accelerated Swiss manufacturing (commercial production in Nidau) to mitigate U.S.-China tariff exposure and scale supply for EVO+ in China; Swiss production expected to provide flexibility, resilience and future margin benefits.
Product and Commercial Momentum
Launched EVO+ in China (first new lens there in more than a decade); expanding Lioli injector availability to EMEA; advancing Stella sizing/ordering platform and finalizing Oracle ERP deployment to drive commercial readiness and efficiency.
Regional Commercial Strength — Americas & U.S.
Americas region up 18% in Q4; management highlighted continued U.S. momentum with double-digit growth in 2025 and expanded U.S. EVO indication (ages 21–60) increasing addressable candidates by roughly 8 million.
STAA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
STAA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 03, 2026 | $18.92 | $19.22 | +1.59% |
Nov 05, 2025 | $25.25 | $26.63 | +5.47% |
Aug 06, 2025 | $26.90 | $26.95 | +0.19% |
May 07, 2025 | $19.44 | $19.53 | +0.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Staar Surgical (STAA) report earnings?
Staar Surgical (STAA) is schdueled to report earning on May 06, 2026, After Close (Confirmed).
What is Staar Surgical (STAA) earnings time?
Staar Surgical (STAA) earnings time is at May 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STAA EPS forecast?
STAA EPS forecast for the fiscal quarter 2026 (Q1) is 0.07.